TipRanks (Wed, 8-Apr 6:30 AM ET)
Alpha Cognition Earnings Call: Early Traction, Rising Costs
TipRanks (Sun, 5-Apr 8:22 PM ET)
Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain Injury
Business Wire (Wed, 1-Apr 4:30 PM ET)
Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update
Business Wire (Thu, 26-Mar 4:01 PM ET)
Business Wire (Fri, 13-Mar 1:46 PM ET)
Business Wire (Tue, 10-Mar 8:30 AM ET)
Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study
Business Wire (Wed, 25-Feb 8:30 AM ET)
Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL Dosing Regimens
Business Wire (Wed, 18-Feb 8:30 AM ET)
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
Alpha Cognition trades on the NASDAQ stock market under the symbol ACOG.
As of April 9, 2026, ACOG stock price declined to $6.38 with 52,684 million shares trading.
ACOG has a beta of 1.81, meaning it tends to be more sensitive to market movements. ACOG has a correlation of 0.16 to the broad based SPY ETF.
ACOG has a market cap of $138.92 million. This is considered a Micro Cap stock.
Last quarter Alpha Cognition reported $3 million in Revenue and -$.30 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.02.
ACOG has outperformed the market in the last year with a price return of +70.1% while the SPY ETF gained +38.4%. However, in the short term, ACOG had mixed performance relative to the market. It has underperformed in the last 3 months, returning -2.7% vs -1.1% return in SPY. But in the last 2 weeks, ACOG shares have fared better than the market returning +19.9% compared to SPY +3.5%.
ACOG support price is $6.22 and resistance is $7.05 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACOG shares will trade within this expected range on the day.
